Comparison

Anti-Human CD257 (BAFF) (Tabalumab)

€4,505.00
Excl. VAT
Item no. LEIN-LT1400-100mg
Manufacturer Leinco Technologies
Amount 100mg
Category
Type Antibody Primary
Applications WB, FC, IF, IP, ELISA, FA
Clone Tabalumab
Specific against other
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Available
info

Antibody Details

Product Details

Reactivity Species

Human/Cynomolgus Monkey/Rabbit


Host Species

Human


Expression Host

HEK-293


FC Effector Activity

Active


Immunogen

Original antibody was raised against soluble human BAFF.

Product Concentration

≥ 5.0 mg/ml


Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method


Purity

≥95% monomer by analytical SEC


Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA


Shipping

Next Day 2-8°C

RRID

AB_2893903

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Tabalumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

FA
N
IP
WB
ELISA
IF

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only.

Antigen Distribution

BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells.

Background

Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects.

Antigen Details

Protein

BAFF

Ligand/Receptor

BR3, TACI, BCMA

PubMed

BAFF

NCBI Gene Bank ID

10673

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Costimulatory Molecules

.

Immunology

.

Signal Transduction

.

Stem Cell


References & Citations

1. Manetta, J. et al. (2014) J Inflamm Res. 7: 121–131

2. Clatworthy, MR. et al. (2013) Transplantation. 96(4): 413–420.

3. Lied, GA. and Berstad, A. (2011) Scand J Immunol. 73(1):1-7.

4. Büchler, JR. and Cano, MN. (1986) Jpn Heart J. 27(1):117-22.

Technical Protocols



Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100mg
Available: In stock
Listprice: €4,505.00
Price: €4,505.00
available

Delivery expected until 9/4/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close